Tivdak™ (tisotumab vedotin-tftv) – New drug approval
On September 20, 2021, Seagen and Genmab announced the FDA approval of Tivdak (tisotumab vedotin-tftv), for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.
Download PDF
